Vincerx Pharma, Inc.

OTC: VINC · Healthcare · Biotechnology

PublicHQ Palo Alto, CA · Santa ClaraCIK 0001796129Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 27

v0.1 · 5/100 weight · pillars only

↑ Piotroski F, balance-sheet leverage · ↓ return on equity, return on assets

Methodology →

Revenue TTM

$1.1M

Rev growth YoY (TTM)

-18.7%

Net income (FY)

-$30.1M

Employees

as of 2026-08-28

Market cap

$68.6k

as of 2026-08-28

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$30.1M-$30.1M2024

Operating income-$31.5M-$31.5M2024

Total assets$8.0M$8.0M2024

Liabilities$5.3M$5.3M2024

Equity$2.7M$2.7M2024

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Vincerx Pharma, Inc.’s financial profile?

Vincerx Pharma, Inc. earned -$30.1M in FY2024 net income.

Peers · Healthcare

Indocan Resources Inc.——Patient Access Solutions, Inc.——Psykey, Inc.——Psyence Biomedical Ltd.——BioTech Medics, Inc.——Adastra Holdings Ltd.——

Neighbors

Santa Clara →

NVIDIA Corporation$215.9B90A Apple Inc.$416.2B84B+Alphabet Inc.$402.8B81B+Broadcom Inc.$63.9B76B+Advanced Micro Devices, Inc.$34.6B78B+Cisco Systems, Inc.$56.7B85A

Key facts

CEORaquel E. Izumi

SectorHealthcare

IndustryBiotechnology

HeadquartersPalo Alto, CA

ExchangeOTC: VINC

Employees13

IPO date2020-05-27

Latest filings

8-K2025-07-07 10-Q2025-05-15 DEF 14A2025-05-12 8-K2025-04-17 8-K2025-04-11 10-K2025-03-27 8-K2025-03-18 8-K2025-02-28

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.